Boehringer Ingelheim Venture Fund has led a $30m series-B round for France-based Eyevensys, a clinical-stage biotechnology company developing non-viral gene therapies for retinal and other ophthalmic diseases.
Fifth Secondaries Market Report also reveals that 97% of secondaries investors are participating in GP-leds
French sponsor beats Ardian and Antin in race for a majority stake in French veterinary chain
Fund is headed by Kirsten Connell and Maria Rotilu and has extended its hard cap to GBP 15m following a first close
BGF exits energy markets consultancy following minority stake investment in 2017